美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Veraxa Biotech Holding AG

1.73

-0.0500-2.81%

盤後：1.760.0300+1.73%19:30 EDT

成交量：14.57萬

成交額：25.66萬

市值：2.45億

市盈率：8.08

高：1.83

開：1.78

低：1.72

收：1.78

52周最高：27.36

52周最低：1.70

股本：1.41億

流通股本：4,101.25萬

量比：1.30

換手率：0.36%

股息：- -

股息率：- -

每股收益(TTM):0.2142

每股收益(LYR):-2.2094

淨資產收益率：-65.29%

總資產收益率：-20.46%

市淨率：6.33

市盈率(LYR):-0.78

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Veraxa Biotech Holding AG

交易所：

NASDAQ

成立時間：

2021

員工人數：

- -

公司地址：

Im Neuenheimer Feld 584,Heidelberg,Baden-Württemberg,Germany

官網：

http://www.veraxa.com

郵編：

69120

電話：

49 6221 3521330

傳真：

- -

簡介：

Veraxa Biotech AG於2025年6月25日在瑞士法律下註冊成立。該公司是一家專註於腫瘤學的生物技術公司，擁有急性髓系白血病的臨床項目，以及用於開發抗體藥物偶聯物和T細胞銜接器的專有平台技術。其目標是建立一個腫瘤學項目管線，旨在為患者實現療效的同時最大限度地減少副作用。

董事

名稱

職位

Adeel Rouf

President, Chief Executive Officer and Director

Warren Hosseinion

Chairman of the Board and Director

Jonathan Intrater

Independent Director

Oded Levy

Independent Director

股東

名稱

職位

Adeel Rouf

President, Chief Executive Officer and Director

Carl von Halem

Interim Chief Financial Officer

Christoph Erkel

Chief Scientific Officer

Warren Hosseinion Jr.

Vice President, Mergers and Acquisitions

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/VRXA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.73,"timestamp":1787688000000,"preClose":1.78,"halted":0,"volume":145678,"hourTrading":{"tag":"盘后","latestPrice":1.76,"preClose":1.73,"latestTime":"19:30 EDT","volume":943,"amount":1639.4676,"timestamp":1787700602848,"change":0.03,"changeRate":0.017341,"amplitude":0.023121},"delay":0,"changeRate":-0.02808988764044946,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"未開盤","change":-0.05,"latestTime":"08-25 16:00:00 EDT","open":1.78,"high":1.825,"low":1.72,"amount":256619.80929,"amplitude":0.058989,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.78,"preHourTrading":{"tag":"盘前","latestPrice":1.82,"preClose":1.78,"latestTime":"09:28 EDT","volume":781,"amount":1432.6424233,"timestamp":1787664513812,"change":0.04,"changeRate":0.022472,"amplitude":0.016461},"postHourTrading":{"tag":"盘后","latestPrice":1.76,"preClose":1.73,"latestTime":"19:30 EDT","volume":943,"amount":1639.4676,"timestamp":1787700602848,"change":0.03,"changeRate":0.017341,"amplitude":0.023121},"volumeRatio":1.2967},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-20.46%","roe":"-65.29%","lyrEps":-2.209413,"volumeRatio":1.2967,"shares":141407813,"dividePrice":0,"high":1.825,"amplitude":0.058989,"preClose":1.78,"low":1.72,"week52Low":1.7,"pbRate":"6.33","week52High":27.36,"institutionHeld":0,"latestPrice":1.73,"eps":0.2142,"divideRate":0,"volume":145678,"delay":0,"ttmEps":0.2142,"open":1.78,"prevYearClose":18.65,"prevWeekClose":1.95,"prevMonthClose":1.76,"prevQuarterClose":1.88,"fiveDayClose":1.79,"twentyDayClose":1.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-08-24","current":8.076564,"percent":0,"low":-1.401348,"twenty":-1.382149,"median":-1.35335,"eighty":-1.340461,"high":-1.331869,"avg":-1.362189,"sd":0.029045,"marketCap":49173764},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-24","current":-1.401348,"twenty":-1.382149,"median":-1.35335,"eighty":-1.340461,"marketCap":49173764}],"updateTime":1787718653285},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":699307581,"yearFounded":2021,"address":"Im Neuenheimer Feld 584,Heidelberg,Baden-Württemberg,Germany","zipCode":"69120","officePhone":"49 6221 3521330"},"stockCompanyDetail":{"websiteUrl":"http://www.veraxa.com","stockEarnings":[{"period":"1week","weight":-0.0335},{"period":"1month","weight":-0.0389},{"period":"3month","weight":-0.9072},{"period":"ytd","weight":-0.9072}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Veraxa Biotech AG於2025年6月25日在瑞士法律下註冊成立。該公司是一家專註於腫瘤學的生物技術公司，擁有急性髓系白血病的臨床項目，以及用於開發抗體藥物偶聯物和T細胞銜接器的專有平台技術。其目標是建立一個腫瘤學項目管線，旨在為患者實現療效的同時最大限度地減少副作用。","exchange":"NASDAQ","name":"Veraxa Biotech Holding AG","nameEN":"Veraxa Biotech Holding AG"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":{"directors":[{"name":"Adeel Rouf","position":"President, Chief Executive Officer and Director"},{"name":"Warren Hosseinion","position":"Chairman of the Board and Director"},{"name":"Jonathan Intrater","position":"Independent Director"},{"name":"Oded Levy","position":"Independent Director"}],"executives":[{"name":"Adeel Rouf","position":"President, Chief Executive Officer and Director"},{"name":"Carl von Halem","position":"Interim Chief Financial Officer"},{"name":"Christoph Erkel","position":"Chief Scientific Officer"},{"name":"Warren Hosseinion Jr.","position":"Vice President, Mergers and Acquisitions"}]}}}